Background The purpose of this study was to determine the role of recombinant activated factor VII (rFVIIa) in abdominal, vascular, and urological surgery.
Introduction
Activated factor VII (FVIIa) plays a key role in hemostasis [1] . The effect of FVIIa is based first on its binding to tissue factor exposed on the subendothelium. The FVIIa-tissue factor complex is formed only in the region of endothelial damage, so that a local hemostasis occurs via the subsequent activation of factors IX and X and the formation of thrombin. After that, thrombin activates platelets and the factors V and VIII at the site of injury. Since 1996, a recombinant activated factor VII (rFVIIa) has been available (NovoSeven ® ; Novo Nordisk A/S, Bagsvaerd, Denmark). The rFVIIa doses used for registered indications (90 μg/kg body weight at intervals of 2 to 3 hours in hemophilia A or B with inhibitors, in acquired hemophilia, and in Glanzmann thrombasthenia and 15 to 30 μg/kg body weight every 4 to 6 hours for the treatment of bleeding in patients with congenital factor VII deficiency) exceed the CI = confidence interval; ERCP = endoscopic retrograde cholangiopancreaticography; FVIIa = activated factor VII; rFVIIa = recombinant activated factor VII.
physiological FVIIa concentration many times over. This results in an additional pharmacodynamic effect: irrespective of tissue factor as rFVIIa activates factor X directly on the surface of the platelets activated at the site of injury, so that large amounts of thrombin develop locally ('thrombin burst') and eventually induce the formation of fibrin from fibrinogen.
Recombinant activated factor VII and prophylaxis of bleeding While the registered indications are rather rare in abdominal and vascular surgery and in urology (hereinafter referred to as 'in the field of abdominal surgery') and are not meant to be further analyzed in this publication, some of the potential indications for rFVIIa listed in Table 1 are more frequent events. Basically, a distinction must be made between bleeding prophylaxis and the treatment of acute bleeding. Two placebocontrolled dose-finding studies are available on bleeding prophylaxis in patients without pre-existing coagulation disorders:
During liver resection, a trend toward reduction of intraoperative blood loss was observed with the higher rFVIIa dose (80 μg/kg) (for example, 1,073 mL versus 1,422 mL on placebo; P = 0.07) [2] . However, the number of patients investigated (n = 63 in the placebo group and n = 59 in the 80 μg/kg rFVIIa group) was too small to achieve a significant result with the proposed reduction of blood loss of approximately 25%. A point of criticism in the design of this study was that rFVIIa was administered prior to the start of the operation, which led to an insufficient rFVIIa level during parenchyma dissection of the liver. In the second placebo-controlled study on the prophylaxis of bleeding, though not directly related to abdominal surgery, a significant reduction of the transfusion rate and perioperative blood loss was seen in retropubic prostatectomy as well as a reduction of the duration of operation in the study group treated with rFVIIa [3] . The small number of patients included in this trial (n = 36) subjects this study to the criticism of a lack of power. Furthermore, it should be noted that a median blood loss of 2,688 mL in the placebo group does not reflect average blood loss in retropubic prostate surgery. The overall study situation in the field of abdominal surgery in patients without pre-existing coagulation disorder does not constitute a sufficient basis to recommend rFVIIa for prophylaxis of severe bleeding.
Recombinant activated factor VII and treatment of bleeding Serious bleeding in abdominal surgical interventions occurs in approximately 2% to 5% of patients [4, 5] . Bleeding complications can be caused or enhanced by coagulation disorders (Table 2) . A marked acquired hemostatic disorder is often seen in massive transfusion (more than 10 units of packed red cells) with dilutional coagulopathy, hyperfibrinolysis, thrombocytopenia, hypothermia, and citrate excess with relative calcium deficiency [6] . In acute bleedings, rFVIIa constitutes an adjunct therapy to the replacement of platelets, fresh frozen plasma, and coagulation factor concentrates in patients with persistent uncontrollable bleeding after all conventional measures have failed, aiming at a rapid cessation of bleeding and thereby achieving (a) a reduction of further blood losses, (b) a reduction of further transfusion requirements, (c) prevention of hemorrhagic shock with subsequent multiple organ fail- Table 1 Registered and potential indications of recombinant activated factor VII in patients undergoing abdominal surgery Registered indications Prophylaxis of bleeding related to surgical or invasive interventions as well as treatment of bleeding in patients with -Congenital hemophilia A or B if inhibitors are present (>5 Bethesda units) or if a strong increase of inhibitors must be expected upon administration of factor VIII or IX [41] -Acquired hemophilia [42] -Congenital factor VII deficiency [43] -Glanzmann thrombasthenia with antibodies to glycoprotein IIb/IIIa and/or human leucocyte antigen and presence or history of refractoriness to platelet concentrates [44] Potential indications Prophylaxis of surgical bleeding in patients with reduced activity or deficiency of coagulation factors, especially with specific inhibitors to plasmatic factors [45] and acquired von Willebrand disease [46] Treatment of bleedings after all conventional measures have failed in patients with -Chronic liver disease [47] -Thrombocytopathy [48] -Platelet-refractory thrombopenia [49] -Bleeding complications due to trauma or surgery in patients without any detectable systemic impairment of hemostasis (references in Tables 3 and 4) -Drug-induced bleeding, especially by hirudine (in connection with supportive measures), danaparoid, fondaparinux, and glycoprotein IIb/IIIa inhibitors [50] ure, and (d) improvement of baseline conditions for possible reoperation.
In this paper, the case reports and case series published to date on the treatment of serious bleeding in the field of abdominal surgery are subjected to a meta-analysis regarding the success of bleeding control or a reduction of bleeding and regarding the correlation of this endpoint with mortality.
Results are discussed keeping in mind that case series, and more likely case reports, are susceptible to publication bias. The risk of thromboembolic complications is analyzed systematically based on the case series with surgical patients and on placebo-controlled studies on the administration of rFVIIa in operated patients.
Materials and methods
In a literature search, the databases Medline, Biosis, Embase, and Current Contents were screened by using key index terms such as rFVIIa, factor VIIa, recombinant activated factor VII, recombinant blood clotting factor 7a, recombinant FVIIa, or NovoSeven ® (period from 1980 to March 2006). The results were used to select clinical data and case reports on the clinical use of rFVIIa in abdominal surgery (no reviews or abstracts from conferences or scientific meetings). Moreover, the references listed in the literature found were looked through and the manufacturer was asked for publications on the subject matter described. All publications found with these key terms were analyzed as to whether they are about patients undergoing abdominal or vascular surgery, without pre-existing coagulation disorder, and treated with rFVIIa due to perioperative bleeding. Reports on trauma patients or patients with abdominal trauma were excluded. Moreover, all publications were analyzed for assessable information on the target variables 'cessation of bleeding or reduction of blood loss' ('reduction or cessation of bleeding'), 'mortality', and 'occurrence of thromboembolic complications'. These target variables were defined as 'met' (responder) or 'not met' (nonresponder) according to the judgment of the authors of the publications reviewed.
To differentiate case series from case reports, the former had to describe at least three patients being treated with rFVIIa for acute bleeding in one publication, at least one of them having to have undergone surgery in the abdominal region. The results of the descriptive analysis were reported in the form of means and ranges.
A subsequently performed meta-analysis of the case series investigated the mean relative frequency of the effects 'reduction or cessation of bleeding', 'mortality', and 'thromboembolism' of the patients treated with rFVIIa in a random effects model. Analysis was based on the assumption that the selected studies constitute a random selection, whose variance to be considered results from the addition of the individual study portion and the estimated variance between the studies. A mean (weighted) effect along with its 95% confidence interval (CI) was calculated for each trial. In a second step, the placebo-controlled studies on the use of rFVIIa in surgical interventions published in the form of congress abstracts or original articles were evaluated with regard to the thromboembolic risk. Therefore, the mean (weighted) odds ratio of all studies was calculated along with the 95% CI, and the results were visualized using forest plots [7] .
Results

Case reports and series
There are no randomized studies on the treatment with rFVIIa for bleeding after and during interventions in the field of abdominal surgery. A literature search revealed 15 published case presentations reporting 17 patients (Table 3 ) and 11 case series (Figure 1 ). While all case reports met the inclusion criteria, one case series with 13 patients was excluded from analysis since the information given in that publication did not allow the operation procedures to be assigned to the individual cases [8] . In the other 10 case series, 50 out of 212 patients received rFVIIa in the context of an intervention in the abdominal region (Figure 1) . The operations performed represent a wide range of major procedures in the field of abdominal surgery (Tables 3 and 4 ). The most frequent ones were operation of aneurysms of the aorta (n = 15) [9] [10] [11] [12] , pancreatic resection (n = 7) [11, [13] [14] [15] [16] [17] , colon resection (n = 8) [11, 13, 18, 19] , splenectomy (n = 5) [11, 12, 17] , and urological operations (n = 8) [9, 13, [20] [21] [22] [23] . Other operations/interventions were aortobifemoral bypass revisions (n = 1) [24] , surgery of infected aortic prothesis (n = 1) [10] , ileocolic anastomosis (n = 1) [13] , operations for morbid obesity (n = 1) [13] , liver hemangioma or liver rupture (n = 2) [13] , ruptured venous malformation (n = 1) [25] and stomach cancer (n = 1) [15] , laparotomy in the case of duodenal ulcer or small bowel resection (n = 3) [11, 26, 27] , hematoma of the abdominal wall (n = 1) [28] or necrotizing enterocolitis (n = 4) [29] , ischemic bowel resection (n = 1) [12] , cholecystectomy (n = 3) [12, 15, 25] , resection of sarcomas or teratomas (n = 2) [30, 31] , hematoma excision (n = 1) [32] , endoscopic retrograde cholangiopancreaticography (ERCP) (n = 1) [13] , and ERCP with sphincterectomy (n = 1) [33] .
Case reports and series: reduction or cessation of bleeding and mortality An effect of rFVIIa was observed in all 17 cases published as case reports (Table 3 ). The 17 patients received an initial dose of 12 to 135 μg/kg body weight rFVIIa. Bleeding was stopped or, at the discretion of the author, reduced or stabilized with one rFVIIa administration in eight patients (Table 3) Flowchart on the analyses of case series Flowchart on the analyses of case series. rFVIIa, recombinant activated factor VII.
(page number not for citation purposes) 23, 30, 33] . In three patients, a close temporal relationship between the administration of rFVIIa and control of bleeding was reported [20, 30, 33] . Six patients received two rFVIIa administrations [16, 17, 19, 24, 28] and three patients received three bolus doses [27, 31, 32] , one of them receiving another seven bolus doses of rFVIIa after the drain losses declined until arterial embolization was performed [27] (Table 3 ).
In two populations of the case series included in the metaanalysis, there is no information on the dose in the subgroup of patients with interventions in the abdominal region [11, 13] .
In the other 30 patients, the initial rFVIIa doses were 30 to 40 μg/kg (n = 8), 80 to 120 μg/kg (n = 12) or 7.2 mg (n = 8), and 300 or 400 μg/kg (n = 2) ( Table 4 ). The number of bolus doses administered was mentioned in seven case series for patients undergoing an operation in the abdominal region. No information on the number of bolus doses administered was found in three case series with a total of 24 patients [11, 13, 15] . Fourteen out of the 26 patients evaluable for the number of bolus doses received a single bolus (54%) [9, 10, 12, 25, 26, 29] , nine patients received two boluses (35%) [9, 10, 12, 18, 29] , two patients three boluses (8%) [13] , and one patient five boluses (4%) [12] ( Table 4) .
The meta-analysis of the case series on the outcome parameters yielded estimated mean effects (random effects model) of 73.2% (95% CI 51.0% to 95.4%) for reduction or cessation of bleeding and 53.0% for survival (95% CI 26.4% to 79.7%, one case series with 11 patients was not evaluable for this parameter). In the population of patients evaluable for survival, a reduction or cessation of bleeding occurred in 29 cases after administration of rFVIIa. In the remaining 10 patients, no reduction of blood losses occurred (Table 4 ) [9, 10, 12, 15, 18, 29] . Only one out of 10 patients in which rFVIIa was not effective survived (10.0%) [15] , whereas 19 out of 29 patients (65.5%) who responded to rFVIIa survived (P = 0.003) (n = 2 [15] , n = 4 [10] , n = 1 [26] , n = 2 [25] , n = 2 [29] , n = 2 [12] , and n = 6 [13] ). Causes of death in spite of a reduction of blood loss after the administration of rFVIIa were multiple organ failure (n = 3 [12] and n = 1 [9] ), persistent need of inotropic support [10] , and persistent hypotension and acidosis [29] or no information was given on the cause of death (n = 3 [13] and n = 1 [15] ).
Case reports and series: thromboembolic complications
Thirteen case reports contain information on side effects [16, [19] [20] [21] [22] [23] [24] 28, 30, 31, 33] , and two patients suffered a thromboembolic event after renal transplantation (partial thrombosis of the femoral vein and of the external iliac vein and common iliac vein [23] ) and deep vein thrombosis at the site of a central venous catheter 1 month after rFVIIa [20] .
Analysis of all case series yielded signs of a thromboembolic complication in six of 36 patients evaluable for this parameter. Besides rFVIIa, other procoagulants administered in the management of severe bleedings should be considered as a possible cause for these events: thrombosis of the iliac vein after colectomy [34] , multiple small pulmonary embolisms after colectomy diagnosed by autopsy [34] , arterial thrombus or transient digital ischemia in two children with arterial catheters [29] , and thrombosis of the aortic graft and the renal artery after operation of a ruptured abdominal aortic aneurysm in one patient [12] . In one patient with hepatic rupture who developed a necrotizing colitis, a causal relationship with the administration of rFVIIa was considered to be possible by the authors [13] .
In three case series (14 patients in total), there was no information on thromboembolic events [9, 10, 15] except the lack of signs of acute thrombosis mentioned for one patient with autopsy [10] . Based on the information from the remaining seven case series [11] [12] [13] 18, 25, 26, 29] with 36 patients, six of which experienced a thromboembolic event, the mean estimated probability of venous or arterial thromboembolisms was calculated to be 16.5% (95% CI 1.2% to 31.8%).
For the meta-analysis of placebo-controlled studies on the administration of rFVIIa in connection with surgical interventions, eight publications were identified, and in these a total of 285 patients received placebo and 555 patients received rFVIIa (Table 5) . rFVIIa was administered for the prophylaxis of bleeding. The mean estimated risks of thromboembolism were 5.97% (95% CI 0.85% to 11.1%) for placebo and 6.42% (95% CI 1.08% to 11.75%) for rFVIIa, with an odds ratio for the entire population of 0.806 (95% CI 0.42 to 1.53) ( Figure  2 ).
Discussion
The meta-analysis of the present case series on the efficacy (reduction or cessation of bleeding) of rFVIIa in patients undergoing an operation in the field of abdominal surgery yielded an estimated mean effect of 73.2% of patients with a 95% CI of 51.0% to 95.4%. A number of case reports, though subject to a publication bias, document efficacy of rFVIIa by reporting a close temporal relationship between the administration of rFVIIa and cessation of bleeding [20, 30, 33] . These results confirm the experiences of different fields of operative medicine [35] , describing the potential of treatment with rFVIIa for the control of serious bleeding in surgical patients.
The rate of cessation or reduction of bleedings after rFVIIa cannot be estimated by the analysis of case reports as these are associated with strong publication bias. Due to a lack of prospective trials, the analysis of case series may yield more reliable results. The mean survival rate of 53.0% determined from nine case series (95% CI 26.4% to 79.7%) demonstrates the poor prognosis of patients with severe postoperative bleeding that could not be controlled with conventional measures. The survival rate of 10.0% in nonresponders to rFVIIa was lower than in patients with reduction or cessation of bleeding after administration of rFVIIa (65.5%; P = 0.003). These results emphasize the relevance of sufficient control of bleeding for the outcome of patients. rFVIIa-refractory bleeding requires immediate measures of bleeding control (reoperation, packing, intraoperative interventional catheter procedures, and so on) to maintain the chance of survival.
Based on more than 10 years of experience with the treatment of patients with hemophilia, the frequency of side effects of rFVIIa can be expected to be less than one side effect per 1,000 standard doses [36] . As with any hemostatic drug, special attention should be given to thromboembolic events. Without a control group and due to the known increased thromboembolic risk of surgical procedures, it is not possible to establish an association with rFVIIa on the basis of the calculated mean rate of thromboembolism of 16.5%. Therefore, we performed an additional meta-analysis of placebo-controlled studies, in which the prophylactic use of rFVIIa was investigated in the context of surgical interventions. No significantly increased risk of thromboembolism was found in any of these studies. Our meta-analysis of studies using rFVIIa for therapeutic rather than prophylactic purposes did not show any significantly increased risk of thromboembolism after administration of rFVIIa compared with placebo. The mean estimated risk of thromboembolism of 6.42% in the eight studies on the prophylaxis of bleeding was within the 95% CI of 1.2% to 31.8% determined for the case series of bleeding therapy. Of note, thromboembolic complications were observed when rFVIIa was administered concomitantly with activated prothrombin complex concentrates (aPCCs) [36, 37] . The thromboembolic risk due to the pretreatment with procoagulatory drugs should be taken into consideration in the benefit-risk assessment but per se does not constitute a contraindication for the administration of rFVIIa [35] .
Since there are no controlled studies on bleeding therapy in abdominal surgery, the formal degree of evidence on the use of rFVIIa in patients with bleeding during and after operations Table 4 Case series on the treatment of severe bleeding with rFVIIa in patients undergoing abdominal surgery without known pre-existing coagulopathy Grounds et al. [13] in the field of abdominal surgery is low and currently corresponds to an expert opinion (degree of evidence C). To safely and effectively tailor the individual treatment of refractory bleeding with coagulation factor concentrates for which no evidence of efficacy can be derived from controlled studies, therapy algorithms considering the severity of bleeding, the patient's general health, and the availability of alternative hemostatic options, and so on can be helpful. Clark and colleagues [9] defined three criteria as a condition for the administration of rFVIIa: (a) transfusions of packed red cells corresponding to at least 1.5-fold the amount of blood volume (>15 units), (b) persistence of severe bleeding in spite of optimal conventional therapy, and (c) no foreseeable immediate surgical bleeding control. The treatment algorithm shown in Figure 3 describes a differentiated therapeutic and diagnostic procedure based on our own clinical experiences as well as on recently published recommendations [35] . It would be desirable to further substantiate this model and to provide evidence of the reduction of morbidity and mortality in randomized studies. The following findings are important when using the algo- Table 5 Thromboembolic events in placebo-controlled studies for the prophylaxis of bleeding with rFVIIa in surgical interventions CI, confidence interval; rFVIIa, recombinant activated factor VII.
Figure 2
Forest plot of thromboembolic events in placebo-controlled studies on the prophylaxis of bleeding with recombinant activated factor VII in surgical interventions Forest plot of thromboembolic events in placebo-controlled studies on the prophylaxis of bleeding with recombinant activated factor VII in surgical interventions.
(page number not for citation purposes) rithm: (a) administration that is too late can compromise the success of treatment, (b) therapy with rFVIIa is useless in moribund patients in desolate overall circumstances, and (c) successful treatment of bleeding implies attempts for correction of acidosis (target pH of ≥7.2), fibrinogen (target of ≥100 mg/ dL), platelets (target of ≥50,000/μL), and hematocrit (target of >24%) [35] which may also impact the efficacy of rFVIIa.
These findings are also supported by individual case series. The three nonresponders reported by Clark and colleagues [9] had already received between 25 and 44 packed red cell units at the time of rFVIIa administration and developed a serious coagulopathy. Mayo and colleagues [15] found that an improvement of the coagulation status had been achieved in patients responding to rFVIIa in the period between ordering of rFVIIa and administering of rFVIIa, whereas this was not the case in the group of nonresponders. Acidosis is associated with a reduced response to rFVIIa [38] , so that its correction is of particular importance. The effect of rFVIIa is less impaired in patients with hypothermia [39] . Nevertheless, a body temperature in the normal range is of benefit to bleeding control [38, 39] .
Nowadays, with the budgeting in the health care system, the considerable costs of rFVIIa are an important factor in treatment decision. Therefore, pharmacoeconomic calculations are required which should involve costs of transfusion and intensive care treatment as well as length of stay in the hospital. Based on a population of patients who had received more than 5 units of packed red blood cells, a hypothetic model was able to demonstrate the cost-effectiveness of rFVIIa for administration after more than 14 units of packed red cells [40] .
Conclusion
The use of rFVIIa in serious bleeding during or after operations in the field of abdominal surgery has been described as effective and safe in various case reports and series. If there are no pre-existing coagulation disorders, there are currently no indications for the prophylactic administration of rFVIIa. However, rFVIIa can be taken into consideration as an additional therapeutic option if serious bleeding was refractory to conventional treatment. The degree of evidence about this corresponds to that of an expert opinion (degree C). According to the experience gained to date and to the placebo-controlled studies, safety is clinically sufficient, although an increased risk of thromboembolism for patients at risk is suspected. Prospective randomized studies need to investigate the efficacy and cost-effectiveness of rFVIIa in this indication in order to allow a final assessment of the importance of this treatment to be made. Diagnostics and measures for massive bleeding in abdominal surgery Diagnostics and measures for massive bleeding in abdominal surgery. rFVIIa, recombinant activated factor VII.
Key messages
• While all case reports documented recombinant activated factor VII (rFVIIa) to be effective, which represents a substantial publication bias, the meta-analysis of the case series showed a reduction of bleeding in 73.2% of patients.
• Patients who responded to the administration of rFVIIa with reduction or cessation of bleeding had a significantly higher probability of survival.
• Thromboembolic complications occurred in six of 36 patients from the case series (16.5%), which was not increased compared with the meta-analysis of thromboembolic events from the eight placebo-controlled studies.
